Fyavolv

Endometriosis, Low Testosterone, Osteoporosis + 16 more
Treatment
20 Active Studies for Fyavolv

What is Fyavolv

NorethisteroneThe Generic name of this drug
Treatment SummaryEthinylestradiol is a synthetic form of the hormone estrogen. It was developed in 1938 by researchers at Schering to allow for better absorption when taken orally. This hormone is used in birth control pills and was approved by the FDA in 1943.
Neconis the brand name
image of different drug pills on a surface
Fyavolv Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Necon
Norethisterone
1967
347

Effectiveness

How Fyavolv Affects PatientsEthinylestradiol is a synthetic form of estrogen that is taken once daily. It works by lowering luteinizing and gonadotrophic hormones, which prevents ovulation and stops the endometrium from developing extra blood vessels. It is a very safe drug, but patients should be aware of the risk of thrombotic events.
How Fyavolv works in the bodyEthinylestradiol is a synthetic form of estrogen. It can be used in combination with other medicines to suppress ovulation, stop sperm from reaching an egg, and prevent a fertilized egg from attaching to the uterus. This medicine also reduces luteinizing hormone levels and increases the body's production of protein that binds to hormones. As a result, estrogen levels in the body decrease, which can lead to lower bone density.

When to interrupt dosage

The measure of Fyavolv is contingent upon the diagnosed condition, including Acne Vulgaris, Hormonal Contraception and Folate supplementation therapy. The dosage fluctuates as per the technique of administration outlined in the table beneath.
Condition
Dosage
Administration
Osteoporosis, Postmenopausal
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Atrophic
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Hormonal Contraception
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Menopause
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
female castration
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Osteoporosis
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Fracture
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Primary Ovarian Insufficiency
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Oral Contraceptives
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Endometriosis
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Endometriosis
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Vasomotor System
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Low Testosterone
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
hypoestrogenism
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Hot flashes
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Birth Control
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Hormone Replacement Therapy
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Estrogen Deprivation Symptoms
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Therapeutic procedure
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
Transdermal, Patch, extended release, , Patch, extended release - Transdermal, Kit, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit - Oral, Patch, Patch - Transdermal, Tablet, chewable, Tablet, chewable - Oral, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Warnings

Fyavolv has twenty-six contraindications, thus it should not be taken when encountering any of the conditions indicated in the following table.Fyavolv Contraindications
Condition
Risk Level
Notes
Liver Diseases
Do Not Combine
Thrombophilia
Do Not Combine
Vaginal Hemorrhage
Do Not Combine
Malignant Neoplasms
Do Not Combine
Benign hepatic neoplasm
Do Not Combine
Breast Cancer
Do Not Combine
Thromboembolism
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Norethisterone may interact with Pulse Frequency
There are 20 known major drug interactions with Fyavolv.
Common Fyavolv Drug Interactions
Drug Name
Risk Level
Description
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Norethisterone.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Norethisterone.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Norethisterone.
Clomipramine
Major
The metabolism of Clomipramine can be increased when combined with Norethisterone.
Copanlisib
Major
The metabolism of Copanlisib can be decreased when combined with Norethisterone.
Fyavolv Toxicity & Overdose RiskWomen who overdose on this drug may experience bleeding, nausea, vomiting, breast tenderness, abdominal pain, drowsiness, and fatigue. To treat the overdose, doctors will monitor potassium and sodium levels and watch for signs of acidosis, while providing supportive treatments.
image of a doctor in a lab doing drug, clinical research

Fyavolv Novel Uses: Which Conditions Have a Clinical Trial Featuring Fyavolv?

38 active research projects are in progress to assess the potential of Fyavolv as a Folate supplementation therapy, Premenstrual Dysphoric Disorder and Menopause treatment.
Condition
Clinical Trials
Trial Phases
Oral Contraceptives
0 Actively Recruiting
Endometriosis
27 Actively Recruiting
Early Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4
Low Testosterone
6 Actively Recruiting
Phase 4, Phase 2, Phase 1
Endometriosis
2 Actively Recruiting
Phase 4, Not Applicable
Hot flashes
19 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3
Osteoporosis
27 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2
Birth Control
22 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2
Estrogen Deprivation Symptoms
0 Actively Recruiting
Osteoporosis, Postmenopausal
0 Actively Recruiting
female castration
0 Actively Recruiting
Atrophic
3 Actively Recruiting
Phase 4, Not Applicable
Hormone Replacement Therapy
0 Actively Recruiting
Hormonal Contraception
0 Actively Recruiting
hypoestrogenism
1 Actively Recruiting
Phase 4
Fracture
0 Actively Recruiting
Vasomotor System
0 Actively Recruiting
Primary Ovarian Insufficiency
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
Menopause
0 Actively Recruiting

Fyavolv Reviews: What are patients saying about Fyavolv?

5Patient Review
1/21/2022
Fyavolv for "Change of Life" Signs
This treatment has allowed me to finally get a good night's sleep. Prior to taking this medication, I was regularly dealing with night sweats.
4.7Patient Review
4/29/2018
Fyavolv for Post-Menopausal Osteoporosis Prevention
This medication has helped me in so many ways. It's alleviated my anger, migraines, and even osteoporosis!
4.3Patient Review
9/30/2020
Fyavolv for "Change of Life" Signs
I'm not sure if it's the thyroid medication I'm on, but I've gained 15lbs since taking this.
4.3Patient Review
8/3/2017
Fyavolv for "Change of Life" Signs

Patient Q&A Section about fyavolv

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Fyavolv used for?

"This medication helps to reduce menopause symptoms (such as hot flashes and vaginal dryness) by replacing the estrogen that the body is no longer producing. The progestin in the medication also helps to reduce the risk of uterine cancer, which can be caused by using estrogen alone."

Answered by AI

Does Fyavolv stop periods?

"If you miss more than one dose or change your schedule, you may not have a period for that month. If you do not take a pill on time, you could have light bleeding or spotting. The more pills you miss, the more likely you are to have bleeding. Take this medicine at the same time each day (with meals or at bedtime)."

Answered by AI

Is Fyavolv a HRT?

"Fyavolv is a combination medicine used to treat symptoms of menopause such as hot flashes, and vaginal dryness, burning, and irritation. It is also used to prevent osteoporosis."

Answered by AI

Does Fyavolv cause weight gain?

"The most common side effects reported were headaches, yeast infections, nausea, cramps, breast tenderness, abdominal pain, mood changes, bacterial infections, acne, irregular bleeding, and weight gain."

Answered by AI

Clinical Trials for Fyavolv

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada
The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.
Phase 4
Recruiting
Erevna Innovations Inc.Andreas Nikolis, MD, PhD
Image of University Hospitals Cleveland Medical Center in Cleveland, United States.

Ketamine for Pelvic Pain

18 - 89
Female
Cleveland, OH
The purpose of this research study is to see if ketamine infusion during surgery can decrease pain after surgery. Ketamine is a medication commonly used as part of anesthesia during surgery and is approved by the US FDA. Patients will be randomized to either receive standard anesthesia with OR without ketamine. The surgical procedure will be the same regardless of which group patients are randomized to. After surgery, patients will be asked to rate their pain in the post-operative observation unit and at their two-week post-operative visit. No additional visits are required for participation in this study. The investigators estimate the surveys will take approximately 10 minutes to complete.
Phase 4
Waitlist Available
University Hospitals Cleveland Medical CenterAdi Cosic, DO
Have you considered Fyavolv clinical trials? We made a collection of clinical trials featuring Fyavolv, we think they might fit your search criteria.Go to Trials
Have you considered Fyavolv clinical trials? We made a collection of clinical trials featuring Fyavolv, we think they might fit your search criteria.Go to Trials
Image of Alethios, Inc. in San Francisco, United States.

NettleEndo for Endometriosis

22 - 45
Female
San Francisco, CA
The goal of this clinical trial is to learn if a wearable brain stimulation device called NettleEndo can reduce chronic pelvic pain and improve wellbeing in women with endometriosis. The study also aims to assess the safety and usability of the device when used at home over several months. The main questions it aims to answer are: 1. Does at-home transcranial direct current stimulation (tDCS) reduce daily pain intensity in women with endometriosis? 2. Does the device also improve mood and sleep quality? Researchers will compare two groups-one receiving active brain stimulation and one receiving a sham (placebo) stimulation-to see if the active device provides greater improvements in symptoms. Participants will: 1. Use the NettleEndo device at home for 20 minutes per session, five times per week for 12 weeks 2. Be randomly assigned to receive either real or sham stimulation through the device 3. Complete daily and weekly symptom ratings through a mobile app 4. Wear an optional fitness tracker to collect data on sleep, movement, and heart rate variability 5. Be followed for 60 days after completing the intervention to monitor longer-term effects All activities are completed remotely using a smartphone app. Participants can contact the study team with questions at any time. The study is double-blind, meaning neither participants nor the researchers assessing outcomes will know who received active or sham treatment until the end of the trial.
Recruiting
Online Trial
Alethios, Inc.Nirav Shah, MD, MPHSamphire Group, Inc.
Image of University of California, San Diego in La Jolla, United States.

Lidocaine for Pain Control in Birth Control

18 - 50
Female
La Jolla, CA
The goal of this research study is to learn more about how different uses of a numbing medication might affect pain levels while getting an IUD placed. The investigators are also studying participants opinions of their clinicians' empathy. The investigators are inviting patients who arrive at their clinic visit seeking an IUD. Usually, at University of California, San Diego (UCSD), for patients who have never delivered a baby, clinicians use a buffered paracervical block for before IUD placement. The purpose of this research study is to investigate whether a "buffered" (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) paracervical block (numbing medication given on both sides of the cervix) is effective in reducing pain during IUD placement in individuals with prior C-sections, the difference between buffered and unbuffered for nulliparous patients, and whether a medicated gel reduces pain with the paracervical block.
Recruiting
Paid Trial
University of California, San DiegoSheila K Mody, MD, MPH
Have you considered Fyavolv clinical trials? We made a collection of clinical trials featuring Fyavolv, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security